soul trial oral semaglutide cardiovascular outcomes 2024 results nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine SOUL: Oral Semaglutide Bests Usual
Pay in 4 interest-free payments of $5.36 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 12 - Nov 17

















/assets/production/practices/438b59b4e27c5dc64b6d75ab18cf4e16804f233b/images/2831064.png)






